Getting paid: New Part B drug pay models intended to boost quality would test providers

Why This Topic Matters

The proposal could affect how a wide range of providers are paid for Part B drugs and how they plan for future reimbursement under a federal demonstration. Understanding the scope and timing helps practices, hospitals, and coding/billing teams assess operational impact and monitor CMS policy changes.

Article Sections

1. Phase I creates two test groups

   Describes the first phase of the CMS payment test, including the broad structure of the comparison groups and the general payment approaches being evaluated. It also notes the categories of drugs excluded from this phase.

2. Phase II introduces new test models

   Summarizes the second phase of the demonstration and the introduction of value-based payment tools. It outlines the broad types of approaches CMS says may be incorporated later in the test.

3. Expect the test in almost every state

   Explains the nationwide scope of the demonstration, how participating service areas are selected, and the special treatment of Maryland. It also includes the proposed comment deadline and resource references.